Healthcare provider profile · identity verified

Ashish Verma, M.D.

Internal Medicine · STURGIS, MI · NPI 1699735936

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	594	188
Levothyroxine Sodium	Levothyroxine Sodium	424	127
Lisinopril	Lisinopril	365	108
Losartan Potassium	Losartan Potassium	363	111
Omeprazole	Omeprazole	339	110
Metoprolol Succinate	Metoprolol Succinate	337	94
Metformin Hcl	Metformin Hcl	311	94
Amlodipine Besylate	Amlodipine Besylate	279	91
Sertraline Hcl	Sertraline Hcl	216	68
Simvastatin	Simvastatin	213	58
Pantoprazole Sodium	Pantoprazole Sodium	200	66
Tamsulosin Hcl	Tamsulosin Hcl	198	70
Furosemide	Furosemide	193	69
Metoprolol Tartrate	Metoprolol Tartrate	169	53
Famotidine	Famotidine	154	49
Duloxetine Hcl	Duloxetine Hcl	150	43
Glipizide Er	Glipizide	149	45
Hydrochlorothiazide	Hydrochlorothiazide	144	44
Meloxicam	Meloxicam	142	62
Fluticasone Propionate	Fluticasone Propionate	140	77
Escitalopram Oxalate	Escitalopram Oxalate	124	37
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	120	41
Eliquis	Apixaban	105	31
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	103	32
Albuterol Sulfate Hfa	Albuterol Sulfate	102	41
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	102	32
Buspirone Hcl	Buspirone Hcl	100	32
Trazodone Hcl	Trazodone Hcl	100	36
Rosuvastatin Calcium	Rosuvastatin Calcium	97	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	96	32
Alendronate Sodium	Alendronate Sodium	93	25
Ibandronate Sodium	Ibandronate Sodium	90	29
Pravastatin Sodium	Pravastatin Sodium	90	29
Lovastatin	Lovastatin	89	23
Carvedilol	Carvedilol	87	27
Tramadol Hcl	Tramadol Hcl	85	23
Gabapentin	Gabapentin	76	36
Potassium Chloride	Potassium Chloride	76	30
Allopurinol	Allopurinol	75	26
Amitriptyline Hcl	Amitriptyline Hcl	74	25
Atenolol	Atenolol	74	21
Xarelto	Rivaroxaban	74	13
Metformin Hcl Er	Metformin Hcl	68	22
Citalopram Hbr	Citalopram Hydrobromide	63	21
Clopidogrel	Clopidogrel Bisulfate	63	21
Pregabalin	Pregabalin	61	25
Fluoxetine Hcl	Fluoxetine Hcl	60	18
Clonazepam	Clonazepam	58	17
Gemfibrozil	Gemfibrozil	55	15
Montelukast Sodium	Montelukast Sodium	52	22
Hydralazine Hcl	Hydralazine Hcl	51	12
Spironolactone	Spironolactone	51	21
Warfarin Sodium	Warfarin Sodium	48	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	45	22
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	42	13
Oxybutynin Chloride	Oxybutynin Chloride	42	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	41	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	40	39
Jardiance	Empagliflozin	40	17
Clonidine Hcl	Clonidine Hcl	39	16
Dutasteride	Dutasteride	39	12
Januvia	Sitagliptin Phosphate	39	14
Ropinirole Hcl	Ropinirole Hcl	39	11
Alprazolam	Alprazolam	38	12
Aripiprazole	Aripiprazole	38	12
Donepezil Hcl	Donepezil Hcl	38	suppressed
Glipizide	Glipizide	36	11
Gavilyte-G	Peg3350/Sod Sulf,bicarb,cl/Kcl	34	34
Ciprofloxacin Hcl	Ciprofloxacin Hcl	33	31
Ezetimibe	Ezetimibe	33	11
Fenofibrate	Fenofibrate Nanocrystallized	32	11
Zolpidem Tartrate	Zolpidem Tartrate	32	13
Paroxetine Hcl	Paroxetine Hcl	31	suppressed
Peg-3350 And Electrolytes	Peg3350/Sod Sulf,bicarb,cl/Kcl	31	29
Enalapril Maleate	Enalapril Maleate	30	11
Novolog Flexpen	Insulin Aspart	30	13
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	30	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	18
Memantine Hcl	Memantine Hcl	29	suppressed
Methylprednisolone	Methylprednisolone	29	22
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Lansoprazole	Lansoprazole	28	suppressed
Ozempic	Semaglutide	28	suppressed
Nystatin	Nystatin	27	18
Prednisone	Prednisone	26	15
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Valsartan	Valsartan	24	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Glimepiride	Glimepiride	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	11
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Carbamazepine	Carbamazepine	18	suppressed
Cefdinir	Cefdinir	18	14
Levetiracetam	Levetiracetam	18	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Cephalexin	Cephalexin	17	15
Finasteride	Finasteride	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Primidone	Primidone	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Metolazone	Metolazone	15	suppressed
Olanzapine	Olanzapine	15	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Niacin Er	Niacin	14	suppressed
Novolin N	Insulin Nph Human Isophane	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	suppressed
Liothyronine Sodium	Liothyronine Sodium	13	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Mesalamine	Mesalamine W/Cleansing Wipes	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Risperidone	Risperidone	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Levofloxacin	Levofloxacin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error